Article Text

Download PDFPDF
Strategies to examine new compounds for intraperitoneal use in ovarian cancer
  1. M. Markman
  1. The University of Texas MD Anderson Cancer Center, Houston, Texas
  1. Address correspondence and reprint requests to: Maurie Markman, MD, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Email: mmarkman{at}


The results of three large well-designed randomized trials demonstrating the favorable impact of primary cisplatin-based chemotherapy on survival in small-volume residual advanced ovarian cancer has stimulated considerable interest in exploration of this route of drug delivery for other antineoplastic agents. A number of relevant properties of both the drugs and the peritoneal cavity need to be considered in preclinical evaluation such that future clinical development will focus on strategies that have a realistic potential for being safe and effective when they enter the clinical arena

  • chemotherapy
  • cisplatin
  • intraperitoneal chemotherapy
  • ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.